Sodium Diet Effect on Aldosterone and Urinary RNA (SALTY)
SALTY
2 other identifiers
interventional
21
1 country
1
Brief Summary
This cross-over clinical trial is being conducted to evaluate the difference in urinary messenger RNA (mRNA) biomarkers of mineralocorticoid receptor activation following a low-sodium diet, as compared to a high-sodium diet. The study team will collect urine and blood samples from each participant to study mineralocorticoid receptor-regulated mRNA biomarkers following the consumption of each diet. The study team will instruct the participants to consume 8 days each of high- (300 mmol/day) and low- (10 mmol/day) sodium meals. The order in which the participants will eat the two study diets will be randomly determined. In between the high- and low-sodium diets, the participants will have a wash-out period of 6 days, during which they will be encouraged to consume their usual diet. Participants will be asked to provide the study team with 24-hour urine samples, random urine samples, and blood samples throughout their participation in this clinical trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable healthy
Started Feb 2020
Typical duration for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 15, 2019
CompletedFirst Posted
Study publicly available on registry
November 19, 2019
CompletedStudy Start
First participant enrolled
February 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 8, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 8, 2021
CompletedDecember 15, 2022
December 1, 2022
1.8 years
November 15, 2019
December 6, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Urinary mineralocorticoid receptor-regulated messenger RNA (mRNA) biomarker
Urinary mRNA biomarkers following consumption of a high-sodium and low-sodium diet will be measured using real-time quantitative polymerase chain reaction (RT-qPCR).
Day 15 (after first diet period)
Urinary mineralocorticoid receptor-regulated mRNA biomarker
Urinary mRNA biomarkers following consumption of a high-sodium and low-sodium diet will be measured using real-time quantitative polymerase chain reaction (RT-qPCR).
Day 29 (after second diet period)
Secondary Outcomes (2)
Blood pressure
Day 15 (after first diet period)
Blood pressure
Day 29 (after second diet period)
Study Arms (2)
High sodium diet
EXPERIMENTALLow sodium diet
EXPERIMENTALInterventions
Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
Eligibility Criteria
You may qualify if:
- Normotensive, as defined by:
- Systolic blood pressure (SBP) \< 140 mmHg and diastolic blood pressure (DBP) \< 90 mmHg
- Never prescribed an antihypertensive medication
- Willingness to refrain from intense exercise (for example, swimming, biking, running)
You may not qualify if:
- Hypertension (history of blood pressure ≥ 140/90 mmHg)
- History of hypertensive urgency, hypertensive crisis, or hospitalizations for hypertension
- History of chronic kidney disease
- History of heart failure
- Current food allergy
- Pregnancy
- Known hyperaldosteronism
- Current mineralocorticoid antagonist use
- Current treatment for diabetes mellitus
- Known adrenal insufficiency
- Current glucocorticoid use
- Electrolyte abnormality on baseline laboratory assessment
- Current potassium supplementation
- Urinary tract infection (UTI)
- Significant renal insufficiency or any other condition thought by the Principal Investigator to place the participant at increased risk of injury during the clinical trial or compromise the scientific integrity of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Michigan
Ann Arbor, Michigan, 48109, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
J Brian Byrd, MD, MS
University of Michigan
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Internal Medicine
Study Record Dates
First Submitted
November 15, 2019
First Posted
November 19, 2019
Study Start
February 12, 2020
Primary Completion
December 8, 2021
Study Completion
December 8, 2021
Last Updated
December 15, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- De-identified data will be deposited into a repository within 1 year of the conclusion of the study.
- Access Criteria
- No additional access restrictions will be placed on the de-identified data, beyond those required by the repository to access or download the data.
We will de-identify participant information and will share it with a trusted repository, such as National Institutes of Health (NIH) Figshare or The Inter-university Consortium for Political and Social Research (ICPSR). We will de-identify and share data obtained from analyzing urinary mRNA biomarkers and measuring the systolic and diastolic blood pressure following consumption of a high-sodium and low-sodium diet. Additionally, specific lab values that support the validity and quality of the study treatment will be shared in a trusted repository.